Evidence map›Paper›PMID 41782130›Full record

ArticleJournal of translational medicine2026

Ripk1-dependent PANoptosis promotes EndMT and aggravates hypoglycemia-related cardiac fibrosis in diabetes.

Shuting Chang, Yuce Peng, Minghao Luo, Dingyi Lv, Na Li, Guanzhao Zhang, Yi Jiang, Dan Ma, Yanyao Huang, Xunjia Li and 3 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shuting ChangDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Yuce PengDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Minghao LuoDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Dingyi LvDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Na LiDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Guanzhao ZhangDepartment of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong, China.
Yi JiangDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Dan MaDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Yanyao HuangDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Xunjia LiDepartment of Nephrology, The First Affiliated Hospital of Chongqing University of Chinese Medicine, Chongqing Traditional Chinese Medicine Hospital, Chongqing, 400021, China.
Deyu ZuoDepartment of Rehabilitation Medicine, The First Affiliated Hospital of Chongqing University of Chinese Medicine, Chongqing Traditional Chinese Medicine Hospital, Chongqing, 400021, China. zuodeyu@cqctcm.edu.cn.
Suxin LuoDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. luosuxin@hospital.cqum.edu.cn.
An HeDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. 204736@hospital.cqmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypoglycemia impairs cardiac function in patients with diabetes, yet its underlying mechanisms remain elusive. Exploring the mechanism of hypoglycemia-related cardiovascular endothelial damage in diabetes from a single-cell perspective and identifying specific intervention measures will assist with preventing adverse cardiovascular events in patients with diabetes.

methodsThis retrospective study includes participants who experienced ≥one hypoglycemia episode from Grade 3A hospitals to elucidate its effect on cardiac function in DM. Single-nucleus (sn) RNA-Seq has been used to determine lineage-specific gene expression, subpopulation composition, and intercellular communication. The findings were further validated through in vivo and in vitro biological assays.

resultsHypoglycemia significantly reduced left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) in both diabetic patients and db/db mice. snRNA-seq of cardiac tissue under hypoglycemic conditions showed significant enrichment of key genes linked to cell death, inflammation, and fibrosis within endothelial cells, macrophages, fibroblasts, and cardiomyocytes, with endothelial cells demonstrating a particularly critical regulatory role. Hypoglycemia triggered Ripk1-dependent PANoptosis in endothelial cells, which was accompanied by EndMT and cardiac fibrosis. Ripk1 knockdown inhibits the activation of the COLLAGEN signaling pathway and attenuates PANoptosis, EndMT, and fibrosis in low glucose-treated Mouse Cardiac Microvascular Endothelial Cells (MCMECs). Correspondingly, endothelial cell-specific Ripk1 conditional knockout improved cardiac function in a diabetichypoglycemia mouse model and effectively mitigated cardiac PANoptosis, EndMT, and COLLAGEN pathway activation.

conclusionsHypoglycemia activates the COLLAGEN signaling pathway through Ripk1-dependent PANoptosis, thereby triggering EndMT and exacerbating cardiac fibrosis. Inhibition of Ripk1 effectively alleviates hypoglycemia-associated cardiac dysfunction.

Indexed as

Endothelial-Mesenchymal TransitionHypoglycemiaMyocardiumReceptor-Interacting Protein Serine-Threonine KinasesAnimalsCollagenEndothelial CellsFibrosisHumansMaleMiceMice, Inbred C57BLSignal TransductionCollagenReceptor-Interacting Protein Serine-Threonine KinasesCardiac fibrosisDiabetesHypoglycemiaPANoptosisRipk1

Identifiers

PMID41782130
PMCPMC13069766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.